General Information of Disease (ID: DISQ9Y50)

Disease Name Malaria
Synonyms plasmodiosis
Disease Class 1F40-1F45: Malaria
Definition
Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. Infection with malaria parasites may result in a wide variety of symptoms, ranging from absent or very mild symptoms to severe disease and even death. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. In general, malaria is a curable disease if diagnosed and treated promptly and correctly.Treatment depends on many factors including disease severity, the species of malaria parasite causing the infection and the part of the world in which the infection was acquired.
Disease Hierarchy
DIS57EB5: Protozoa infectious disease
DISGFCIX: Vector-borne disease
DISDMSC5: Erythrocyte disorder
DISQ9Y50: Malaria
ICD Code
ICD-11
ICD-11: 1F40-1F45
ICD-9
ICD-9: 84
Expand ICD-9
84
Disease Identifiers
MONDO ID
MONDO_0005136
MESH ID
D008288
UMLS CUI
C0024530
MedGen ID
7443
Orphanet ID
673
SNOMED CT ID
105649009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 31 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Amodiaquine DME4RA8 Approved Small molecular drug [1]
ARH-1 DMY7SEH Approved NA [2]
Arteether DMQLX7O Approved Small molecular drug [3]
Artemether DM48QOT Approved Small molecular drug [4]
Artemisinin DMOY7W3 Approved Small molecular drug [4]
Artemisinin SP DMFETDK Approved Small molecular drug [4]
Artesunate DMR27C8 Approved Small molecular drug [4]
Chloroquine DMSI5CB Approved Small molecular drug [5]
Chlorproguanil DM1IFGT Approved Small molecular drug [4]
Curemisinin DM7K7V9 Approved NA [2]
Dihydroartemisinin DMBXVMZ Approved Small molecular drug [4]
Fosmidomycin DM7G0EP Approved Small molecular drug [4]
Halofantrine DMOMK1V Approved Small molecular drug [6]
Hydroxychloroquine DMSIVND Approved Small molecular drug [7]
Insulin-glargine DMR4HIW Approved Small molecular drug [8]
Lumefantrine DM29GAD Approved Small molecular drug [2]
Malaria vaccine DMPFNSH Approved NA [2]
MCB-3837 DM0R4Z5 Approved Small molecular drug [9]
Mefloquine DMWT905 Approved Small molecular drug [10]
Meprobamate DMHM93Y Approved Small molecular drug [4]
OZ277 DM1YB0R Approved Small molecular drug [4]
Piperaquine DMT70RC Approved Small molecular drug [4]
Primaquine DMWQ16I Approved Small molecular drug [11]
Proguanil DMBL79I Approved Small molecular drug [12]
Pyrimethamine DM5X7VY Approved Small molecular drug [13]
Pyronaridine DMUWAM2 Approved Small molecular drug [2]
Quinine DMSWYF5 Approved Small molecular drug [14]
Sulphadoxine DMZI2UF Approved Small molecular drug [4]
Tafenoquine DM1XT4N Approved Small molecular drug [15]
Triclosan DMZUR4N Approved Small molecular drug [16]
Ustekinumab DMHTYK3 Approved Antibody [17]
------------------------------------------------------------------------------------
⏷ Show the Full List of 31 Drug(s)
This Disease is Treated as An Indication in 42 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Mosquirix malaria recombinant vaccine DMQ0NDI Preregistration NA [18]
Fosclin DM8L3JU Phase 3 NA [19]
GSK-1437173A DMDOFDG Phase 3 NA [20]
MK-3415A DMGNHC2 Phase 3 Antibody [21]
Pafuramidine DMFKOR9 Phase 3 Small molecular drug [22]
Artemisone DM15VBJ Phase 2/3 Small molecular drug [23]
AQ-13 DM1USXR Phase 2 Small molecular drug [24]
Ferroquine DMICMXE Phase 2 Small molecular drug [25]
FMP2.1/AS02A DM3JMRU Phase 2 NA [26]
GSK3437949A DMTGY65 Phase 2 Vaccine [27]
KAF156 DMN4H8N Phase 2 NA [28]
Malaria next generation vaccine DMJHNXI Phase 2 NA [29]
Merozoite surface protein 3 long synthetic peptide vaccine DMGWNYS Phase 2 NA [30]
NITD609 DMQHBSX Phase 2 Small molecular drug [31]
OZ-439 DME7V7X Phase 2 NA [32]
PEV3A DM9HJBP Phase 2 NA [33]
PfSPZ vaccine DMX5D1D Phase 2 Vaccine [34]
PfSPZ-Cvac DM6IN4U Phase 2 NA [35]
PlaMavax DMYUO6B Phase 2 Vaccine [36]
SAR97276 DMG9MN2 Phase 2 Small molecular drug [37]
Ad35.CS.01 DMD4SGZ Phase 1/2 NA [38]
AdCh63 AMA1 DMEGPSW Phase 1/2 Vaccine [39]
AdCh63-MSP1 DMBGXH5 Phase 1/2 Vaccine [39]
DNA-Ad DM71BFM Phase 1/2 Vaccine [40]
Malaria DNA vaccine DMN279C Phase 1/2 NA [41]
MuStDO 5 DMTUL6H Phase 1/2 NA [42]
P52-/p36- GAP vaccine DMSRNUU Phase 1/2 NA [43]
PfCS-102 DMD01Y3 Phase 1/2 NA [44]
AdVac Malaria Vaccine DM8JZOC Phase 1 NA [45]
BNT165 DM3G2GK Phase 1 Vaccine [46]
CDRI-97/78 DM049IX Phase 1 NA [47]
EP-1300 DM0UH4M Phase 1 NA [48]
GMZ-2 DMD6H8B Phase 1 Vaccine [49]
GSK3772701 DMTPFYC Phase 1 NA [50]
ISOQUINE DMR17YI Phase 1 Small molecular drug [51]
JAIVAC-1 DMO4AMV Phase 1 NA [52]
MalariVax DMCHYK8 Phase 1 NA [53]
P-27A DMWM6ZM Phase 1 NA [54]
PfAMA-1 DMLDZX1 Phase 1 Vaccine [55]
Sanaria PfSPZ Vaccine DMY6LGC Phase 1 NA [56]
SERA5-targeted malaria vaccine DMDV32Y Phase 1 NA [57]
SPF66 DMTLYGW Phase 1 NA [58]
------------------------------------------------------------------------------------
⏷ Show the Full List of 42 Drug(s)
This Disease is Treated as An Indication in 5 Patented Agent(s)
Drug Name Drug ID Highest Status Drug Type REF
PMID30280939-Compound-US20170128558 DMM83WL Patented Vaccine [59]
PMID30280939-Compound-US20179642901 DMPVW2Q Patented Vaccine [59]
PMID30280939-Compound-WO2008009652 DM7DG0M Patented Vaccine [59]
PMID30280939-Compound-WO2013148426 DMUKIEJ Patented Vaccine [59]
PMID30280939-Compound-WO2015091734 DM5K3DF Patented Vaccine [59]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Preclinical Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
GSK-932121A DMP3M20 Preclinical NA [60]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 3 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
MMV00/0053 DMF27BS Terminated NA [61]
Pepstatin DM9S1EA Terminated Small molecular drug [62]
Plasmodium falciparum LSA-NRC vaccine DM7GDFD Terminated NA [63]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 42 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
5,8-Dihydroxy-1,4-naphthoquinone DMOCEPA Investigative Small molecular drug [64]
AMA-1-Dico DMHCWLS Investigative NA [65]
AN-3661 DM7TC2N Investigative NA [65]
Antimalarial peroxides DMKFXIX Investigative NA [65]
Antimalarials DM2Z1K3 Investigative NA [65]
ARTELINIC ACID DMGOHYP Investigative Small molecular drug [66]
Buthionine sulfoximine DMJ46CB Investigative Small molecular drug [64]
CDRI-99/411 DMZ95F8 Investigative NA [65]
Cycloguanil DMC520D Investigative Small molecular drug [12]
DC-480 DMZHSGJ Investigative NA [65]
DSM1 DM1LK0C Investigative NA [67]
DSM2 DMZYQOB Investigative NA [67]
Genz-667348 DMMAUEB Investigative NA [65]
Genz-668764 DMIPRNN Investigative Small molecular drug [65]
Glyphosate DM0AFY7 Investigative Small molecular drug [68]
GSK-1137585 DMS7PDF Investigative NA [65]
IMX-MSP3 DMUQDAN Investigative NA [65]
JBD-411 DM37NFU Investigative NA [65]
JD-3000 DMY1VFX Investigative NA [65]
K-510 DMAHIB4 Investigative NA [65]
KAC-776 DMIBS1T Investigative NA [65]
Leupeptin DMU075F Investigative Small molecular drug [64]
Lm-Malaria DMS0VIY Investigative NA [65]
MG-3 DMQL4AM Investigative NA [65]
MK-4815 DMT9K74 Investigative NA [65]
Molecule 23 DMD3SIZ Investigative NA [65]
Monoxanes DM6APHE Investigative NA [65]
MVA CSP DMINH0L Investigative NA [65]
ND-901 DM8FSYV Investigative NA [65]
Oxindole derivative DM1AU8V Investigative Small molecular drug [64]
P-218 DM5OKZB Investigative NA [65]
Pfs48 DML7P8T Investigative NA [65]
SAR-116242 DMHFZT6 Investigative NA [65]
SOM-0888 DM1T32W Investigative NA [65]
SSJ-183 DM6A42S Investigative Small molecular drug [65]
T-2 DMSD3ND Investigative Small molecular drug [69]
T-3.5 DM3Q1HL Investigative NA [65]
Tetraoxane derivatives DMOYETN Investigative NA [65]
Thiolactomycin DMBAWDG Investigative Small molecular drug [70]
Thiophene sulfonamide DMAKW2S Investigative Small molecular drug [71]
VLD-517 DM3WZTF Investigative NA [65]
WRR-276 DMDGQ5O Investigative NA [65]
------------------------------------------------------------------------------------
⏷ Show the Full List of 42 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 102 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
AGRP TT4DE1O Limited Biomarker [72]
AQP3 TTLDNMQ Limited Biomarker [73]
CD27 TTDO1MV Limited Genetic Variation [74]
CDC25C TTESBNC Limited Biomarker [75]
CDK5R1 TTBYM6V Limited Biomarker [76]
CHIT1 TTDYX6T Limited Biomarker [77]
CXCL11 TTWG0RE Limited Biomarker [78]
CXCL9 TTWE5PB Limited Altered Expression [78]
DNAJB1 TTPXAWS Limited Biomarker [79]
EBI3 TTJF68X Limited Genetic Variation [80]
FKBP4 TTHY0FT Limited Altered Expression [81]
GLO1 TTV9A7R Limited Biomarker [82]
ICOS TTE5VP6 Limited Biomarker [83]
IRAK4 TTILUKB Limited Biomarker [84]
IRF1 TT4TU3L Limited Altered Expression [85]
KIR2DS1 TTVWAGF Limited Genetic Variation [86]
KIR3DL2 TTQH3N0 Limited Genetic Variation [86]
METAP2 TTZL0OI Limited Biomarker [87]
MVD TTE5J6X Limited Altered Expression [88]
NFKB2 TTKLNRV Limited Altered Expression [81]
NQO2 TTJLP0R Limited Biomarker [89]
PRDX5 TTLPJWH Limited Biomarker [90]
PSIP1 TTH9LDP Limited Altered Expression [81]
RNF34 TTEWDK1 Limited Biomarker [91]
SGCG TTSMT9W Limited Biomarker [92]
SLC6A7 TT9LGO5 Limited Biomarker [93]
TAP1 TT7JZI8 Limited Biomarker [94]
TLR6 TTWRI8V Limited Genetic Variation [95]
TLR7 TTRJ1K4 Limited Biomarker [96]
TMPRSS11D TTWHYC8 Limited Biomarker [97]
TNFRSF18 TTG6LA7 Limited Genetic Variation [98]
TPT1 TT3PTB6 Limited Biomarker [99]
UMPS TTAFJUD Limited Genetic Variation [100]
XPO1 TTCJUR4 Limited Biomarker [101]
LANCL1 TTZW8NS Disputed Biomarker [102]
NEK2 TT3VZ24 Disputed Biomarker [103]
ADAMTS13 TTUREBK moderate Altered Expression [104]
NOS2 TTF10I9 moderate Genetic Variation [105]
TLR1 TTW14D0 moderate Genetic Variation [106]
TNF TTF8CQI moderate Genetic Variation [107]
ACHE TT1RS9F Strong Biomarker [108]
ACKR1 TTKY2NS Strong Biomarker [109]
ACTG1 TTGAZF9 Strong Biomarker [110]
ANK1 TTKFPMH Strong Biomarker [111]
ATR TT8ZYBQ Strong Biomarker [112]
CD55 TT5Z9WY Strong Biomarker [113]
CFH TTUW6OP Strong Biomarker [114]
CPB1 TT4UJX5 Strong Biomarker [115]
CYP2D6 TTVG215 Strong Biomarker [116]
DHODH TTLVP78 Strong Biomarker [117]
DHPS TTBO2A9 Strong Genetic Variation [118]
ERAP1 TT60XFL Strong Biomarker [119]
FCGR2B TT5RWKQ Strong Genetic Variation [120]
FCGR3A TTIFOC0 Strong Altered Expression [121]
GEM TTAZF9M Strong Genetic Variation [86]
GRK5 TTTCXO0 Strong Genetic Variation [122]
GSR TTEP6RV Strong Biomarker [123]
HAMP TTRV5YJ Strong Biomarker [124]
HLA-G TTLKFB3 Strong Genetic Variation [125]
HP TTLC8E1 Strong Biomarker [126]
HSP90AA1 TT78R5H Strong Biomarker [127]
HSPB3 TTLH8WG Strong Biomarker [128]
ICAM1 TTA1L39 Strong Biomarker [129]
IFNAR1 TTSYFMA Strong Genetic Variation [130]
IL12B TTGW72V Strong Genetic Variation [131]
LAIR1 TTSI7A8 Strong Altered Expression [132]
LTBR TTFO0PM Strong Biomarker [133]
MECP2 TTTAU9R Strong Biomarker [134]
MIF TT6804T Strong Biomarker [135]
PDXK TTXI3KF Strong Altered Expression [136]
PKLR TT31N4S Strong Genetic Variation [137]
PNP TTMCF1Y Strong Biomarker [138]
S1PR3 TTDYP7I Strong Altered Expression [139]
SLC44A4 TT0NYDG Strong Biomarker [140]
SORT1 TTRX9AV Strong Biomarker [141]
TEP1 TTQGAVX Strong Biomarker [142]
TFRC TT8MG4S Strong Biomarker [143]
THBD TTAPV67 Strong Biomarker [144]
TIRAP TTKU0LS Strong Biomarker [145]
TYMS TTP1UKZ Strong Biomarker [146]
USP1 TTG9MT5 Strong Genetic Variation [147]
ASPA TT6TLZP Definitive Genetic Variation [148]
CD160 TTOFEAS Definitive Altered Expression [149]
CNTF TTGEM5Q Definitive Biomarker [150]
CR2 TT0HUN7 Definitive Genetic Variation [74]
CTSC TT4H0V2 Definitive Biomarker [151]
EIF5A TTIVCNR Definitive Biomarker [152]
FECH TTQ6VF4 Definitive Biomarker [153]
IDE TT2EDHU Definitive Biomarker [154]
KIR2DL2 TTU0P73 Definitive Altered Expression [155]
KIR2DL3 TTEX3SI Definitive Biomarker [156]
LTB TTHQ6US Definitive Biomarker [157]
MASP2 TTR01E9 Definitive Biomarker [158]
PDXP TT9UYG4 Definitive Biomarker [90]
PGD TTZ3IFB Definitive Genetic Variation [159]
PRKG1 TT7IZSA Definitive Biomarker [160]
PRSS1 TT2WR1T Definitive Biomarker [161]
RAB7A TTF6WAQ Definitive Altered Expression [162]
SERPIND1 TT8XSKJ Definitive Altered Expression [163]
SPAG6 TTDAKTW Definitive Biomarker [164]
TPH1 TTZSJHV Definitive Biomarker [165]
TRPC1 TTA76X0 Definitive Biomarker [161]
------------------------------------------------------------------------------------
⏷ Show the Full List of 102 DTT(s)
This Disease Is Related to 3 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC11A1 DT650XW Limited Genetic Variation [166]
SLC25A21 DT2UQYR Definitive Biomarker [167]
SLC4A1 DTB0Q3P Definitive Genetic Variation [168]
------------------------------------------------------------------------------------
This Disease Is Related to 3 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
CYP2C8 DES5XRU Limited Genetic Variation [169]
HK1 DEDMAGE Limited Biomarker [170]
PGM1 DEA3VM1 Strong Biomarker [171]
------------------------------------------------------------------------------------
This Disease Is Related to 199 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
AKAP13 OTOZAR14 Limited Biomarker [172]
ARTN OTWIWGL6 Limited Biomarker [72]
CARD16 OT4NUHWB Limited Biomarker [173]
CCL1 OT23NON8 Limited Altered Expression [174]
CCL4 OT6B8P25 Limited Biomarker [175]
CCL4L2 OTDBSXOU Limited Biomarker [175]
CD1B OT4D5EG7 Limited Biomarker [176]
CHP1 OTHTXN1A Limited Biomarker [177]
CLEC11A OT9KBH7C Limited Biomarker [172]
CNTNAP1 OT5Y03EU Limited Biomarker [178]
COQ2 OTDAKEY4 Limited Genetic Variation [179]
COX3 OTNNGBYJ Limited Biomarker [180]
CSH1 OT33HTRR Limited Genetic Variation [181]
CSH2 OTW8JVAN Limited Genetic Variation [181]
DENND2B OT7UH61B Limited Biomarker [182]
EGR3 OTGPJIRA Limited Genetic Variation [183]
ERCC8 OT0T4WKI Limited Genetic Variation [181]
FCN2 OTTHJBKZ Limited Genetic Variation [184]
FMN1 OT9CID5R Limited Biomarker [185]
GTF2H4 OTPD1DIU Limited Altered Expression [81]
GYPC OTOEDR7O Limited Genetic Variation [186]
H6PD OTO7TNDD Limited Biomarker [187]
HAP1 OT6SG0JQ Limited Biomarker [188]
HBG2 OT4J48JJ Limited Altered Expression [189]
HM13 OTGEO1LP Limited Biomarker [190]
HTN3 OTEUXA81 Limited Genetic Variation [191]
IFNGR1 OTCTQBWW Limited Genetic Variation [192]
IL10RA OTOX3D1D Limited Genetic Variation [193]
IL12RB1 OTM1IJO2 Limited Altered Expression [85]
ING1 OTEZBRKW Limited Biomarker [172]
ITGAX OTOGIMHE Limited Biomarker [144]
LMAN1 OTYHKDEO Limited Genetic Variation [194]
MCF2 OTB9N93T Limited Biomarker [195]
NANP OTR0RNB1 Limited Biomarker [196]
NFYA OTWFFOVH Limited Biomarker [188]
NRSN1 OT1KKXC8 Limited Biomarker [177]
NSFL1C OTIKQF3U Limited Biomarker [172]
NT5C3A OT67KZJA Limited Biomarker [197]
ORC1 OTHWU8IJ Limited Genetic Variation [198]
PANX1 OTXPEDOK Limited Biomarker [199]
PGLS OTO6C0IQ Limited Altered Expression [200]
PLEK OTB73XXA Limited Biomarker [172]
RAB39B OTDCLLT0 Limited Biomarker [201]
RCAN1 OT1MVXC7 Limited Biomarker [101]
RHOF OTPA3F8Q Limited Biomarker [91]
RNASE3 OTVE2XD1 Limited Genetic Variation [202]
SAFB OTGRV2LW Limited Biomarker [203]
SEPTIN9 OT1VMRFQ Limited Genetic Variation [204]
SMIM10L2B OT04IG2N Limited Biomarker [205]
TMED2 OTBLO7RW Limited Biomarker [177]
TPPP OTCFMSUF Limited Biomarker [76]
ANXA7 OTLMD0TK Disputed Genetic Variation [206]
ARL6IP5 OTYZ6BEQ Disputed Genetic Variation [207]
ARMH1 OTTJC0D6 Disputed Biomarker [102]
CARTPT OTTE4V9S Disputed Biomarker [208]
CBX5 OT8VYY84 Disputed Altered Expression [209]
CDCA5 OTZLCQ5U Disputed Biomarker [102]
DHX16 OTW8KZAU Disputed Genetic Variation [210]
EBNA1BP2 OTBRVMZH Disputed Biomarker [102]
ELK4 OTVSSEOE Disputed Genetic Variation [211]
FUT9 OTLIJBQY Disputed Genetic Variation [212]
GCHFR OTEOT8GI Disputed Biomarker [102]
MAP2 OT6UYT3X Disputed Biomarker [213]
PRRC2A OTBX6FM5 Disputed Genetic Variation [214]
PSAP OTUOEKY7 Disputed Genetic Variation [211]
PSMD7 OT7PZZ4K Disputed Biomarker [102]
PTPRH OTDUHQGF Disputed Genetic Variation [211]
RABEPK OTCZSREH Disputed Biomarker [102]
RBM25 OTVOUOAG Disputed Biomarker [215]
SCLT1 OT2ZSSP4 Disputed Genetic Variation [211]
SPPL3 OT2HLJF6 Disputed Biomarker [216]
SPTA1 OT1YMP65 Disputed Genetic Variation [217]
TCN2 OT41D0L3 Disputed Genetic Variation [218]
ABCG4 OT2XJIOG Strong Genetic Variation [219]
ACD OTC54EPO Strong Biomarker [220]
ACOT7 OT7C68YV Strong Biomarker [110]
ACTBL2 OTD6B81U Strong Biomarker [110]
ACTG2 OTRDWUO0 Strong Biomarker [110]
ADA2 OTGCV24S Strong Genetic Variation [221]
ADGRE1 OTQQ9Q7G Strong Biomarker [222]
AQP4 OTA9MYD5 Strong Biomarker [223]
CD1C OT4XINUJ Strong Biomarker [144]
CD1E OT4F3AKI Strong Biomarker [224]
CDH13 OTD2CYM5 Strong Genetic Variation [225]
CSMD1 OTIVDSC4 Strong Genetic Variation [226]
DDT OTF5HTYL Strong Biomarker [227]
DDX39B OTEVCFVU Strong Genetic Variation [228]
DHX9 OT5AAOQI Strong Biomarker [229]
DNAJC5 OTCZDXAL Strong Biomarker [230]
ELF4 OT167PR5 Strong Biomarker [231]
EMP1 OTSZHUHQ Strong Biomarker [232]
ENOSF1 OT65D3ZK Strong Biomarker [134]
FCGR2C OTNLMNYB Strong Biomarker [137]
FCGR3B OTSLSPZG Strong Altered Expression [121]
FHL5 OT6C00Z1 Strong Biomarker [110]
FLT3LG OTU0YGC4 Strong Biomarker [233]
GYPA OTABU4YV Strong Biomarker [234]
GYPB OTESHUIX Strong Biomarker [234]
GYPE OTBHAG6A Strong Biomarker [234]
HBE1 OTJPKMX4 Strong Genetic Variation [235]
HSPA4 OT5HR0AR Strong Biomarker [236]
IARS1 OT9WXH5N Strong Altered Expression [237]
ILF3 OTKMZ5K5 Strong Biomarker [238]
INSRR OT3F75WA Strong Biomarker [239]
ISYNA1 OT49ONSE Strong Genetic Variation [105]
ITPA OTQ47WVR Strong Biomarker [240]
KARS1 OT0EU4SV Strong Biomarker [241]
KCNG1 OTZ9ZRG8 Strong Genetic Variation [242]
KIR3DL1 OTPOSXFX Strong Genetic Variation [86]
KLHL3 OTEJ6850 Strong Genetic Variation [226]
KRT13 OTTYSKGX Strong Genetic Variation [242]
LAMP3 OTN0XL3W Strong Biomarker [243]
LEO1 OTAPF4PA Strong Genetic Variation [244]
LSAMP OTYXVQX2 Strong Biomarker [243]
MMP26 OT9O89KU Strong Genetic Variation [225]
MNAT1 OTXLOYCB Strong Biomarker [197]
MYLK4 OTN16PNF Strong Biomarker [245]
NBEAL2 OTMCAXWR Strong Biomarker [246]
NCR3 OT20M764 Strong Genetic Variation [247]
NUDT2 OTMHM1DH Strong Biomarker [240]
OMD OTFRELBB Strong Biomarker [248]
OR10A4 OTYYB8SY Strong Biomarker [249]
OR51B5 OTQ1MHRJ Strong Genetic Variation [235]
PEX19 OTQIDE9Z Strong Biomarker [250]
PIEZO1 OTBG1FU4 Strong Genetic Variation [251]
POMGNT2 OT0S9Z0J Strong Genetic Variation [252]
POTEM OT7L2HGH Strong Biomarker [110]
PROCR OTRHED17 Strong Genetic Variation [253]
PUM3 OTN1IPNS Strong Biomarker [254]
RECQL4 OT59LSW7 Strong Biomarker [134]
SERPINA3 OT9BP2S0 Strong Biomarker [110]
SPATA3 OT026AAA Strong Genetic Variation [252]
SPINK5 OT61IIAO Strong Biomarker [255]
SSR2 OTQJSL7M Strong Genetic Variation [256]
STK24 OTGUHOIL Strong Biomarker [257]
STK3 OTLNSCQD Strong Genetic Variation [257]
TADA2A OTXUMEL9 Strong Genetic Variation [221]
TIMD4 OTGGC20G Strong Genetic Variation [258]
TMED9 OTYGAQS0 Strong Biomarker [76]
TOLLIP OTYEO4NR Strong Genetic Variation [259]
TRAF3IP2 OTLLZERL Strong Biomarker [260]
TREML4 OT2VLMTL Strong Genetic Variation [226]
A1CF OTJBKFA1 Definitive Genetic Variation [148]
ADIRF OTTJP8D4 Definitive Biomarker [261]
ANXA4 OTUCRYXL Definitive Biomarker [262]
APCDD1 OTV9AD0L Definitive Biomarker [263]
ARMC9 OT0MZER2 Definitive Biomarker [164]
BTNL2 OTTTEMZA Definitive Biomarker [264]
CCL3L1 OTQXCYB1 Definitive Genetic Variation [265]
CCNI OT8863O1 Definitive Biomarker [266]
CERS1 OT6EYRM3 Definitive Biomarker [175]
CFC1 OT5DHGI8 Definitive Biomarker [267]
CFDP1 OTXY7J96 Definitive Biomarker [268]
CGAS OTJYIXNB Definitive Biomarker [269]
CPQ OTTNZNLD Definitive Altered Expression [270]
CYC1 OT0962IM Definitive Biomarker [266]
DBP OTE0W7LN Definitive Biomarker [271]
DSTN OTMXO4YB Definitive Biomarker [272]
EHD1 OTDMEKLV Definitive Genetic Variation [273]
EIF4G2 OTEO98CR Definitive Biomarker [268]
EIF5 OT79PQUN Definitive Biomarker [152]
EIF5AL1 OTLA4ONW Definitive Biomarker [152]
ERFE OTSES1HA Definitive Biomarker [274]
GDF1 OTZ1VRBH Definitive Biomarker [175]
GEMIN4 OTX7402E Definitive Biomarker [268]
GTF3A OTVROUVQ Definitive Biomarker [275]
HBG1 OTVL4NSU Definitive Altered Expression [276]
HPR OTXSC9UB Definitive Altered Expression [277]
IL17RE OTMFTNLS Definitive Genetic Variation [278]
KIR2DS5 OTXLEN11 Definitive Altered Expression [279]
KIR3DS1 OTJWIO4T Definitive Genetic Variation [280]
LUC7L OT77JDB7 Definitive Genetic Variation [281]
MAF OT1GR3IZ Definitive Biomarker [282]
MAP6 OTPUI00F Definitive Genetic Variation [283]
MCPH1 OTYT3TT5 Definitive Biomarker [284]
MOGS OT99MBGB Definitive Biomarker [285]
MPPE1 OTINBJVE Definitive Biomarker [286]
NLRP12 OTGR132Z Definitive Altered Expression [287]
PARS2 OTMBBH7K Definitive Biomarker [288]
PGAM1 OTZ5DB06 Definitive Biomarker [289]
PLP1 OT8CM9CX Definitive Biomarker [90]
POFUT2 OT1MNJFZ Definitive Biomarker [290]
POLD4 OTG578YH Definitive Biomarker [291]
POLE4 OTCMWUT6 Definitive Biomarker [291]
PSMD2 OT6HZHN7 Definitive Biomarker [268]
PTPMT1 OT9WVC6N Definitive Biomarker [292]
RAB14 OTF1J0TB Definitive Altered Expression [293]
RAB7B OT60A0E9 Definitive Altered Expression [162]
RANBP2 OTFG5CVF Definitive Biomarker [161]
RBP2 OTR8QG5V Definitive Biomarker [294]
RNPS1 OT7G4COD Definitive Genetic Variation [295]
ROPN1L OTRWZJ68 Definitive Genetic Variation [148]
SEMA3C OTEGUY7F Definitive Genetic Variation [296]
SEPTIN4 OTD16B30 Definitive Genetic Variation [297]
SLC22A18 OT9C3KR4 Definitive Biomarker [298]
SPO11 OTP49B2R Definitive Biomarker [299]
TADA1 OTV9RKSL Definitive Genetic Variation [300]
TREML1 OTMJD2HI Definitive Genetic Variation [301]
TRIM5 OTMZH7EJ Definitive Biomarker [302]
------------------------------------------------------------------------------------
⏷ Show the Full List of 199 DOT(s)

References

1 Drug information of Amodiaquine, 2008. eduDrugs.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 The role of natural product chemistry in drug discovery. J Nat Prod. 2004 Dec;67(12):2141-53.
4 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5535).
6 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 020250.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7198).
8 ClinicalTrials.gov (NCT02059161) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003). U.S. National Institutes of Health.
9 How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
10 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 019578
11 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 008316.
12 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
13 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4800).
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2510).
15 Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523.
16 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
17 Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother. 2002 Nov;46(11):3362-9.
18 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011712)
19 ClinicalTrials.gov (NCT00214643) Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children. U.S. National Institutes of Health.
20 ClinicalTrials.gov (NCT01767467) Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With BloodCancers. U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT01513239) A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002). U.S. National Institutes of Health.
22 ClinicalTrials.gov (NCT00302341) DB289 Versus TMP-SMX for the Treatment of Acute Pneumocystis Jiroveci Pneumonia (PCP). U.S. National Institutes of Health.
23 ClinicalTrials.gov (NCT00936767) Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia. U.S. National Institutes of Health.
24 ClinicalTrials.gov (NCT01614964) Studies of a Candidate Aminoquinoline Antimalarial (AQ-13). U.S. National Institutes of Health.
25 ClinicalTrials.gov (NCT00988507) Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria. U.S. National Institutes of Health.
26 ClinicalTrials.gov (NCT00460525) Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali. U.S. National Institutes of Health.
27 Clinical pipeline report, company report or official report of GlaxoSmithKline.
28 ClinicalTrials.gov (NCT01753323) Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection. U.S. National Institutes of Health.
29 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
30 Breman JG, Alilio MS, White NJ Northbrook (IL): American Society of Tropical Medicine and Hygiene, 2007 Dec.
31 ClinicalTrials.gov (NCT01836458) A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection. U.S. National Institutes of Health.
32 ClinicalTrials.gov (NCT02083380) Phase IIb Study to Investigate the Efficacy of OZ439 & Piperaquine Phosphate Co-administered to Adults & Children With Uncomplicated Plasmodium Falciparum.. U.S. National Institutes of Health.
33 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019935)
34 ClinicalTrials.gov (NCT03989102) Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali. U.S. National Institutes of Health.
35 ClinicalTrials.gov (NCT03503058) Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria. U.S. National Institutes of Health.
36 ClinicalTrials.gov (NCT01658696) Efficacy of Candidate Malaria Vaccines in Senegalese Adults. U.S. National Institutes of Health.
37 ClinicalTrials.gov (NCT00739206) Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.. U.S. National Institutes of Health.
38 ClinicalTrials.gov (NCT01397227) A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model. U.S. National Institutes of Health.
39 ClinicalTrials.gov (NCT01142765) Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP. U.S. National Institutes of Health.
40 ClinicalTrials.gov (NCT00870987) Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria. U.S. National Institutes of Health.
41 Clinical trial in healthy malaria-na ve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother. 2012 November 1; 8(11): 1564-1584.
42 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010309)
43 ClinicalTrials.gov (NCT01024686) Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine. U.S. National Institutes of Health.
44 ClinicalTrials.gov (NCT01031524) Trial to Assess the Efficacy of Malaria Vaccine PfCS 102. U.S. National Institutes of Health.
45 Clinical pipeline report, company report or official report of Crucell.
46 ClinicalTrials.gov (NCT05581641) An Exploratory Phase I, Randomized, Observer-blind, Placebo-controlled Dose Escalation Trial Evaluating the Safety, Tolerability and Immunogenicity of an Investigational RNA-based Vaccine for Active Immunization Against Malaria. U.S.National Institutes of Health.
47 Simultaneous quantification of proposed anti-malarial combination comprising of lumefantrine and CDRI 97-78 in rat plasma using the HPLC-ESI-MS/MS method: application to drug interaction study. MalarJ. 2015 Apr 22;14:172.
48 ClinicalTrials.gov (NCT01169077) EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria. U.S. National Institutes of Health.
49 ClinicalTrials.gov (NCT00424944) Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine. U.S. National Institutes of Health.
50 Clinical pipeline report, company report or official report of GlaxoSmithKline
51 Antimalarial activity of isoquine against Kenyan Plasmodium falciparum clinical isolates and association with polymorphisms in pfcrt and pfmdr1 genes. J Antimicrob Chemother. 2013 Apr;68(4):786-8.
52 Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175. PLoS One. 2015 Apr 30;10(4):e0117820.
53 ClinicalTrials.gov (NCT00587249) ICC-1132 - Candidate Vaccine Against P Falciparum Malaria. U.S. National Institutes of Health.
54 ClinicalTrials.gov (NCT01949909) Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib. U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT00431808) Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]). U.S. National Institutes of Health.
56 ClinicalTrials.gov (NCT01546389) Sanaria PfSPZ Challenge Vaccine. U.S. National Institutes of Health.
57 Clinical pipeline report, company report or official report of BIKEN.
58 Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia. Am J Trop Med Hyg. 1997 May;56(5):526-32.
59 Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.Expert Opin Ther Pat. 2018 Nov;28(11):837-847.
60 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019156)
61 Annual report of Medicines for Malaria Venture in 2002.
62 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004280)
63 Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun. 2005 Apr;73(4):2109-15.
64 Novel molecular targets for antimalarial chemotherapy. Int J Antimicrob Agents. 2007 Jul;30(1):4-10.
65 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
66 Artesunate and artelinic acid: association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats. Birth Defects Res B Dev Reprod Toxicol. 2011 Feb;92(1):52-68.
67 Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect Disord Drug Targets. 2010 Jun;10(3):226-39.
68 The apicoplast as an antimalarial drug target. Drug Resist Updat. 2001 Jun;4(3):145-51.
69 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6648).
70 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.
71 Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
72 Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria.Int J Pharm. 2019 May 1;562:162-171. doi: 10.1016/j.ijpharm.2019.03.031. Epub 2019 Mar 19.
73 Plasmodium parasite exploits host aquaporin-3 during liver stage malaria infection.PLoS Pathog. 2018 May 18;14(5):e1007057. doi: 10.1371/journal.ppat.1007057. eCollection 2018 May.
74 Malaria-induced interferon- drives the expansion of Tbethi atypical memory B cells.PLoS Pathog. 2017 Sep 27;13(9):e1006576. doi: 10.1371/journal.ppat.1006576. eCollection 2017 Sep.
75 Association between cytosolic low molecular weight phosphotyrosine-phosphatase and malaria--a possible mechanism.Am J Phys Anthropol. 1999 Feb;108(2):241-4. doi: 10.1002/(SICI)1096-8644(199902)108:2<241::AID-AJPA9>3.0.CO;2-Z.
76 Immunization with Transgenic Rodent Malaria Parasites Expressing Pfs25 Induces Potent Transmission-Blocking Activity.Sci Rep. 2018 Jan 25;8(1):1573. doi: 10.1038/s41598-017-18831-8.
77 High levels of human chitotriosidase hinder the formation of peritrophic membrane in anopheline vectors.Parasitol Res. 2007 Apr;100(5):1033-9. doi: 10.1007/s00436-006-0372-z. Epub 2006 Nov 29.
78 Chemokines responses to Plasmodium falciparum malaria and co-infections among rural Cameroonians.Parasitol Int. 2015 Apr;64(2):139-44. doi: 10.1016/j.parint.2014.11.003. Epub 2014 Nov 16.
79 Hsp70s and J proteins of Plasmodium parasites infecting rodents and primates: structure, function, clinical relevance, and drug targets.Curr Pharm Des. 2013;19(3):387-403. doi: 10.2174/138161213804143734.
80 Interferon- (IFNG) microsatellite repeat and single nucleotide polymorphism haplotypes of IFN- receptor (IFNAR1) associated with enhanced malaria susceptibility in Indian populations.Infect Genet Evol. 2015 Jan;29:6-14. doi: 10.1016/j.meegid.2014.10.030. Epub 2014 Nov 7.
81 Plasmodium berghei p52&p36 parasites develop independent of a parasitophorous vacuole membrane in Huh-7 liver cells.PLoS One. 2012;7(12):e50772. doi: 10.1371/journal.pone.0050772. Epub 2012 Dec 5.
82 Activity, regulation, copy number and function in the glyoxalase system.Biochem Soc Trans. 2014 Apr;42(2):419-24. doi: 10.1042/BST20140008.
83 Inducible Costimulator Expressing T Cells Promote Parasitic Growth During Blood Stage Plasmodium berghei ANKA Infection.Front Immunol. 2018 May 28;9:1041. doi: 10.3389/fimmu.2018.01041. eCollection 2018.
84 Divergent roles of IRAK4-mediated innate immune responses in two experimental models of severe malaria.Am J Trop Med Hyg. 2010 Jul;83(1):69-74. doi: 10.4269/ajtmh.2010.09-0753.
85 Interferon regulatory factor modulation underlies the bystander suppression of malaria antigen-driven IL-12 and IFN- in filaria-malaria co-infection.Eur J Immunol. 2012 Mar;42(3):641-50. doi: 10.1002/eji.201141991. Epub 2012 Jan 19.
86 Killer cell immunoglobulin-like receptor (KIR) gene diversity in a population naturally exposed to malaria in Porto Velho, Northern Brazil.Tissue Antigens. 2015 Mar;85(3):190-9. doi: 10.1111/tan.12523. Epub 2015 Feb 6.
87 Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo.Chem Biol. 2009 Feb 27;16(2):193-202. doi: 10.1016/j.chembiol.2009.01.006.
88 Risk factors of malaria infection during pregnancy in Burkina Faso: suggestion of a genetic influence.Am J Trop Med Hyg. 1993 Mar;48(3):358-64. doi: 10.4269/ajtmh.1993.48.358.
89 Can a proteomics strategy be used to identify the anti-malarial activity of chloroquine?.Trends Pharmacol Sci. 2003 May;24(5):210-2; discussion 212-3. doi: 10.1016/S0165-6147(03)00071-3.
90 Ornithine Decarboxylase Inhibition: A Strategy to Combat Various Diseases.Mini Rev Med Chem. 2018;18(12):1008-1021. doi: 10.2174/1389557517666170927130526.
91 Recognition of variant Rifin antigens by human antibodies induced during natural Plasmodium falciparum infections.Infect Immun. 2002 Dec;70(12):7013-21. doi: 10.1128/IAI.70.12.7013-7021.2002.
92 Molecular approaches to malaria: MAM 2004 and beyond.Trends Parasitol. 2004 Dec;20(12):547. doi: 10.1016/j.pt.2004.09.001.
93 Malaria and ovalocytosis--molecular mimicry?.Biochim Biophys Acta. 1991 Apr 15;1096(3):263-4. doi: 10.1016/0925-4439(91)90014-z.
94 CD8+ T cells specific for a malaria cytoplasmic antigen form clusters around infected hepatocytes and are protective at the liver stage of infection.Infect Immun. 2013 Oct;81(10):3825-34. doi: 10.1128/IAI.00570-13. Epub 2013 Jul 29.
95 Influence of polymorphisms in toll-like receptors (TLRs) on malaria susceptibility in low-endemic area of the Atlantic Forest, So Paulo, Brazil.Acta Trop. 2018 Jun;182:309-316. doi: 10.1016/j.actatropica.2018.03.011. Epub 2018 Mar 15.
96 Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host.Bioorg Med Chem Lett. 2019 May 1;29(9):1099-1105. doi: 10.1016/j.bmcl.2019.02.029. Epub 2019 Feb 27.
97 Diagnosis of human sleeping sickness: sense and sensitivity.Trends Parasitol. 2011 Sep;27(9):394-402. doi: 10.1016/j.pt.2011.04.005. Epub 2011 Jun 12.
98 Novel regulatory SNPs in the promoter region of the TNFRSF18 gene in a Gabonese population.Braz J Med Biol Res. 2011 May;44(5):418-20. doi: 10.1590/S0100-879X2011007500036. Epub 2011 Mar 29.
99 Immunological memory to blood-stage malaria infection is controlled by the histamine releasing factor (HRF) of the parasite.Sci Rep. 2017 Aug 22;7(1):9129. doi: 10.1038/s41598-017-09684-2.
100 A unique insertion of low complexity amino acid sequence underlies protein-protein interaction in human malaria parasite orotate phosphoribosyltransferase and orotidine 5'-monophosphate decarboxylase.Asian Pac J Trop Med. 2014 Mar;7(3):184-92. doi: 10.1016/S1995-7645(14)60018-3.
101 ELISA detection of vivax malaria with recombinant multiple stage-specific antigens and its application to survey of residents in endemic areas.Korean J Parasitol. 2003 Dec;41(4):203-7. doi: 10.3347/kjp.2003.41.4.203.
102 A replication study of the association between the IL12B promoter allele CTCTAA and susceptibility to cerebral malaria in Thai population.Malar J. 2009 Dec 11;8:290. doi: 10.1186/1475-2875-8-290.
103 An essential role for the Plasmodium Nek-2 Nima-related protein kinase in the sexual development of malaria parasites.J Biol Chem. 2009 Jul 31;284(31):20858-68. doi: 10.1074/jbc.M109.017988. Epub 2009 Jun 2.
104 Reduced ADAMTS13 activity is associated with an ADAMTS13 SNP, fever and microparticles in a malaria-like model.Malar J. 2014 Jan 3;13:3. doi: 10.1186/1475-2875-13-3.
105 iNOS polymorphism modulates iNOS/NO expression via impaired antioxidant and ROS content in P. vivax and P. falciparum infection.Redox Biol. 2018 May;15:192-206. doi: 10.1016/j.redox.2017.12.005. Epub 2017 Dec 14.
106 A common TLR1 polymorphism is associated with higher parasitaemia in a Southeast Asian population with Plasmodium falciparum malaria.Malar J. 2016 Jan 6;15:12. doi: 10.1186/s12936-015-1071-y.
107 Evolutionary interplay of single nucleotide polymorphisms at the promoter region of TNF- gene in different clinical outcomes of malaria in India.Infect Genet Evol. 2019 Apr;69:107-116. doi: 10.1016/j.meegid.2019.01.025. Epub 2019 Jan 21.
108 3-Oxoisoxazole-2(3H)-carboxamides and isoxazol-3-yl carbamates: Resistance-breaking acetylcholinesterase inhibitors targeting the malaria mosquito, Anopheles gambiae. Bioorg Med Chem. 2015 Mar 15;23(6):1321-40.
109 Genome-Wide Characterization of Arabian Peninsula Populations: Shedding Light on the History of a Fundamental Bridge between Continents.Mol Biol Evol. 2019 Mar 1;36(3):575-586. doi: 10.1093/molbev/msz005.
110 Mass drug administration can be a valuable addition to the malaria elimination toolbox.Malar J. 2019 Aug 22;18(1):281. doi: 10.1186/s12936-019-2906-8.
111 A novel ENU-mutation in ankyrin-1 disrupts malaria parasite maturation in red blood cells of mice.PLoS One. 2012;7(6):e38999. doi: 10.1371/journal.pone.0038999. Epub 2012 Jun 19.
112 Infrared spectroscopy coupled to cloud-based data management as a tool to diagnose malaria: a pilot study in a malaria-endemic country.Malar J. 2019 Oct 16;18(1):348. doi: 10.1186/s12936-019-2945-1.
113 Beyond the Role of CD55 as a Complement Component.Immune Netw. 2018 Feb 20;18(1):e11. doi: 10.4110/in.2018.18.e11. eCollection 2018 Feb.
114 Quantification of human complement factor H binding to asexual malaria blood stages by an enzyme-linked immunosorbent assay.Vaccine. 2018 Mar 14;36(12):1545-1547. doi: 10.1016/j.vaccine.2018.01.080. Epub 2018 Feb 12.
115 Identification, Molecular Characterization, and In Silico Structural Analysis of Carboxypeptidase B2 of Anopheles stephensi.J Med Entomol. 2019 Jan 8;56(1):72-85. doi: 10.1093/jme/tjy127.
116 Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.BMC Infect Dis. 2019 Aug 9;19(1):704. doi: 10.1186/s12879-019-4357-9.
117 Increased stress associated with head-out plethysmography testing can exacerbate respiratory effects and lead to mortality in rats.J Pharmacol Toxicol Methods. 2019 Sep-Oct;99:106580. doi: 10.1016/j.vascn.2019.106580. Epub 2019 May 11.
118 Population genetic study of Plasmodium falciparum parasites pertaining to dhps gene sequence in malaria endemic areas of Assam.Indian J Med Microbiol. 2015 Jul-Sep;33(3):401-5. doi: 10.4103/0255-0857.158565.
119 Ankylosing Spondylitis: A Trade Off of HLA-B27, ERAP, and Pathogen Interconnections? Focus on Sardinia.Front Immunol. 2019 Jan 25;10:35. doi: 10.3389/fimmu.2019.00035. eCollection 2019.
120 Association between Fc-gamma receptor IIa (CD32) gene polymorphism and malaria susceptibility: a meta-analysis based on 6928 subjects.Infect Genet Evol. 2014 Apr;23:169-75. doi: 10.1016/j.meegid.2014.02.011. Epub 2014 Mar 1.
121 Plasmodium falciparum Activates CD16+ Dendritic Cells to Produce Tumor Necrosis Factor and Interleukin-10 in Subpatent Malaria.J Infect Dis. 2019 Jan 29;219(4):660-671. doi: 10.1093/infdis/jiy555.
122 Categorical complexities of Plasmodium falciparum malaria in individuals is associated with genetic variations in ADORA2A and GRK5 genes.Infect Genet Evol. 2015 Aug;34:188-99. doi: 10.1016/j.meegid.2015.06.010. Epub 2015 Jun 9.
123 Determination of the inhibitory effects of N-methylpyrrole derivatives on glutathione reductase enzyme.J Enzyme Inhib Med Chem. 2019 Dec;34(1):51-54. doi: 10.1080/14756366.2018.1520228.
124 Update of pre- and postnatal iron supplementation in malaria endemic settings.Semin Perinatol. 2019 Aug;43(5):291-296. doi: 10.1053/j.semperi.2019.03.019. Epub 2019 Mar 16.
125 The role of HLA-G in parasitic diseases.HLA. 2018 Apr;91(4):255-270. doi: 10.1111/tan.13196. Epub 2018 Jan 25.
126 A Proteogenomic Analysis of Haptoglobin in Malaria.Proteomics Clin Appl. 2018 Jul;12(4):e1700077. doi: 10.1002/prca.201700077. Epub 2017 Nov 23.
127 Identification of Hsp90 Inhibitors with Anti-Plasmodium Activity.Antimicrob Agents Chemother. 2018 Mar 27;62(4):e01799-17. doi: 10.1128/AAC.01799-17. Print 2018 Apr.
128 Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.Clin Infect Dis. 2019 Sep 27;69(8):1377-1384. doi: 10.1093/cid/ciy1087.
129 Sodium arsenite exposure impairs B cell proliferation and enhances vascular inflammation in Plasmodium berghei mouse model.Environ Toxicol Pharmacol. 2019 Feb;66:7-13. doi: 10.1016/j.etap.2018.12.010. Epub 2018 Dec 16.
130 Type I Interferon Receptor Variants in Gene Regulatory Regions are Associated with Susceptibility to Cerebral Malaria in Malawi.Am J Trop Med Hyg. 2018 Jun;98(6):1692-1698. doi: 10.4269/ajtmh.17-0887. Epub 2018 Apr 5.
131 Cord Blood IL-12 Confers Protection to Clinical Malaria in Early Childhood Life.Sci Rep. 2018 Jul 18;8(1):10860. doi: 10.1038/s41598-018-29179-y.
132 Public antibodies to malaria antigens generated by two LAIR1 insertion modalities.Nature. 2017 Aug 31;548(7669):597-601. doi: 10.1038/nature23670. Epub 2017 Aug 23.
133 Testosterone responsiveness of spleen and liver in female lymphotoxin beta receptor-deficient mice resistant to blood-stage malaria.Microbes Infect. 2005 Mar;7(3):399-409. doi: 10.1016/j.micinf.2004.11.016. Epub 2005 Feb 26.
134 Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers.Hum Vaccin Immunother. 2020;16(1):33-41. doi: 10.1080/21645515.2019.1643675. Epub 2019 Aug 15.
135 Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection.Nat Commun. 2018 Jul 13;9(1):2714. doi: 10.1038/s41467-018-05041-7.
136 Low erythrocyte pyridoxal-kinase activity in Blacks: Its possible relation to falciparum malaria.Lancet. 1978 Mar 4;1(8062):466-8. doi: 10.1016/s0140-6736(78)90133-2.
137 Pyruvate Kinase and Fc Receptor Gene Copy Numbers Associated With Malaria Phenotypes.J Infect Dis. 2017 Jul 15;216(2):276-282. doi: 10.1093/infdis/jix284.
138 Genetic resistance to purine nucleoside phosphorylase inhibition in Plasmodium falciparum.Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2114-2119. doi: 10.1073/pnas.1525670115. Epub 2018 Feb 12.
139 Expression of sphingosine kinase 1 and sphingosine 1-phosphate receptor 3 in malaria-associated acute lung injury/acute respiratory distress syndrome in a mouse model.PLoS One. 2019 Sep 4;14(9):e0222098. doi: 10.1371/journal.pone.0222098. eCollection 2019.
140 Solution structure, glycan specificity and of phenol oxidase inhibitory activity of Anopheles C-type lectins CTL4 and CTLMA2.Sci Rep. 2019 Oct 23;9(1):15191. doi: 10.1038/s41598-019-51353-z.
141 The malaria parasite Plasmodium falciparum Sortilin is essential for merozoite formation and apical complex biogenesis.Cell Microbiol. 2018 Aug;20(8):e12844. doi: 10.1111/cmi.12844. Epub 2018 Apr 30.
142 Anopheles gambiae TEP1 forms a complex with the coiled-coil domain of LRIM1/APL1C following a conformational change in the thioester domain.PLoS One. 2019 Jun 25;14(6):e0218203. doi: 10.1371/journal.pone.0218203. eCollection 2019.
143 Cryo-EM structure of the human ferritin-transferrin receptor 1 complex.Nat Commun. 2019 Mar 8;10(1):1121. doi: 10.1038/s41467-019-09098-w.
144 Functional Human CD141+ Dendritic Cells in Human Immune System Mice.J Infect Dis. 2020 Jan 2;221(2):201-213. doi: 10.1093/infdis/jiz432.
145 Association of TLR variants with susceptibility to Plasmodium vivax malaria and parasitemia in the Amazon region of Brazil.PLoS One. 2017 Aug 29;12(8):e0183840. doi: 10.1371/journal.pone.0183840. eCollection 2017.
146 Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics.Science. 2018 Jan 12;359(6372):191-199. doi: 10.1126/science.aan4472.
147 Prevalence of Plasmodium falciparum delayed clearance associated polymorphisms in adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific protease 1 (pfubp1) genes in Ghanaian isolates.Parasit Vectors. 2018 Mar 12;11(1):175. doi: 10.1186/s13071-018-2762-3.
148 Genotyping of the Duffy blood group among Plasmodium knowlesi-infected patients in Malaysia.PLoS One. 2014 Sep 30;9(9):e108951. doi: 10.1371/journal.pone.0108951. eCollection 2014.
149 HVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage.Front Immunol. 2018 Nov 13;9:2611. doi: 10.3389/fimmu.2018.02611. eCollection 2018.
150 Expression of interleukin-6 family receptors in NK92 cells is regulated by cytokines and not through direct interaction with Plasmodium falciparum-infected erythrocytes.J Interferon Cytokine Res. 2013 Feb;33(2):65-71. doi: 10.1089/jir.2012.0094.
151 Simultaneous ATR-FTIR Based Determination of Malaria Parasitemia, Glucose and Urea in Whole Blood Dried onto a Glass Slide.Anal Chem. 2017 May 16;89(10):5238-5245. doi: 10.1021/acs.analchem.6b04578. Epub 2017 Apr 28.
152 Deoxyhypusine hydroxylase from Plasmodium vivax, the neglected human malaria parasite: molecular cloning, expression and specific inhibition by the 5-LOX inhibitor zileuton.PLoS One. 2013;8(3):e58318. doi: 10.1371/journal.pone.0058318. Epub 2013 Mar 7.
153 Malaria parasite-synthesized heme is essential in the mosquito and liver stages and complements host heme in the blood stages of infection.PLoS Pathog. 2013;9(8):e1003522. doi: 10.1371/journal.ppat.1003522. Epub 2013 Aug 1.
154 High-Sensitivity Assays for Plasmodium falciparum Infection by Immuno-Polymerase Chain Reaction Detection of PfIDEh and PfLDH Antigens.J Infect Dis. 2017 Sep 15;216(6):713-722. doi: 10.1093/infdis/jix369.
155 Killer-cell immunoglobulin-like receptors and malaria caused by Plasmodium falciparum in The Gambia.Tissue Antigens. 2012 Feb;79(2):104-13. doi: 10.1111/j.1399-0039.2011.01818.x.
156 Significant association of KIR2DL3-HLA-C1 combination with cerebral malaria and implications for co-evolution of KIR and HLA.PLoS Pathog. 2012;8(3):e1002565. doi: 10.1371/journal.ppat.1002565. Epub 2012 Mar 8.
157 A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults.Malar J. 2010 Oct 29;9:302. doi: 10.1186/1475-2875-9-302.
158 Mutations of complement lectin pathway genes MBL2 and MASP2 associated with placental malaria.Malar J. 2012 Mar 2;11:61. doi: 10.1186/1475-2875-11-61.
159 Sequence conservation of Plasmodium vivax glutamate dehydrogenase among Korean isolates and its application in seroepidemiology.Malar J. 2017 Jan 3;16(1):3. doi: 10.1186/s12936-016-1653-3.
160 The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony.Eukaryot Cell. 2010 Jan;9(1):37-45. doi: 10.1128/EC.00186-09. Epub 2009 Nov 13.
161 Motility precedes egress of malaria parasites from oocysts.Elife. 2017 Jan 24;6:e19157. doi: 10.7554/eLife.19157.
162 Impaired placental autophagy in placental malaria.PLoS One. 2017 Nov 10;12(11):e0187291. doi: 10.1371/journal.pone.0187291. eCollection 2017.
163 Measuring health facility readiness and its effects on severe malaria outcomes in Uganda.Sci Rep. 2018 Dec 18;8(1):17928. doi: 10.1038/s41598-018-36249-8.
164 The Armadillo repeat protein PF16 is essential for flagellar structure and function in Plasmodium male gametes.PLoS One. 2010 Sep 23;5(9):e12901. doi: 10.1371/journal.pone.0012901.
165 Diagnostic accuracy of a LAMP kit for diagnosis of imported malaria in Switzerland.Travel Med Infect Dis. 2015 Mar-Apr;13(2):167-71. doi: 10.1016/j.tmaid.2014.12.016. Epub 2015 Jan 7.
166 Genetic dissection of the molecular pathogenesis of severe infection.Intensive Care Med. 2000;26 Suppl 1:S89-97. doi: 10.1007/s001340051124.
167 Vitamin B6-dependent enzymes in the human malaria parasite Plasmodium falciparum: a druggable target?.Biomed Res Int. 2014;2014:108516. doi: 10.1155/2014/108516. Epub 2014 Jan 9.
168 Southeast Asian AE1 associated renal tubular acidosis: cation leak is a class effect.Biochem Biophys Res Commun. 2009 May 15;382(4):668-72. doi: 10.1016/j.bbrc.2009.03.062. Epub 2009 Mar 14.
169 Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007 Aug;82(2):197-203.
170 Anti-peptide antibodies differentiate between plasmodial lactate dehydrogenases.Peptides. 2010 Apr;31(4):525-32. doi: 10.1016/j.peptides.2010.01.002. Epub 2010 Jan 20.
171 Resistance to falciparum malaria among adults in central Sudan.Am J Trop Med Hyg. 1986 Jan;35(1):45-55. doi: 10.4269/ajtmh.1986.35.45.
172 Plasmodium P47: a key gene for malaria transmission by mosquito vectors.Curr Opin Microbiol. 2017 Dec;40:168-174. doi: 10.1016/j.mib.2017.11.029. Epub 2017 Dec 8.
173 Characterisation of a delta-COP homologue in the malaria parasite, Plasmodium falciparum.Mol Biochem Parasitol. 2002 Aug 7;123(1):11-21. doi: 10.1016/s0166-6851(02)00117-2.
174 Host response to malaria during pregnancy: placental monocyte recruitment is associated with elevated beta chemokine expression.J Immunol. 2003 Mar 1;170(5):2759-64. doi: 10.4049/jimmunol.170.5.2759.
175 A Time Series Analysis: Weather Factors, Human Migration and Malaria Cases in Endemic Area of Purworejo, Indonesia, 2005-2014.Iran J Public Health. 2018 Apr;47(4):499-509.
176 Identifying and structurally characterizing CD1b in Aotus nancymaae owl monkeys.Immunogenetics. 2004 Oct;56(7):480-9. doi: 10.1007/s00251-004-0716-8. Epub 2004 Sep 10.
177 Malaria infection induces virus expression in human immunodeficiency virus transgenic mice by CD4 T cell-dependent immune activation.J Infect Dis. 2001 Apr 15;183(8):1260-8. doi: 10.1086/319686. Epub 2001 Mar 9.
178 Processing, polymorphism, and biological significance of P190, a major surface antigen of the erythrocytic forms of Plasmodium falciparum.Mol Biochem Parasitol. 1984 Apr;11:61-80. doi: 10.1016/0166-6851(84)90055-0.
179 Humoral response to defined Plasmodium falciparum antigens in cerebral and uncomplicated malaria and their relationship to parasite genotype.Am J Trop Med Hyg. 1997 Apr;56(4):430-5. doi: 10.4269/ajtmh.1997.56.430.
180 Rapid and sensitive multiplex single-tube nested PCR for the identification of five human Plasmodium species.Parasitol Int. 2018 Jun;67(3):277-283. doi: 10.1016/j.parint.2018.01.005. Epub 2018 Jan 31.
181 Antibodies that inhibit binding of Plasmodium falciparum-infected erythrocytes to chondroitin sulfate A and to the C terminus of merozoite surface protein 1 correlate with reduced placental malaria in Cameroonian women.Infect Immun. 2004 Mar;72(3):1603-7. doi: 10.1128/IAI.72.3.1603-1607.2004.
182 Malaria diagnosis: standardization of a polymerase chain reaction for the detection of Plasmodium falciparum parasites in individuals with low-grade parasitemia.Parasitol Res. 1996;82(7):612-6. doi: 10.1007/s004360050173.
183 Profiling the malaria genome: a gene survey of three species of malaria parasite with comparison to other apicomplexan species.Mol Biochem Parasitol. 2001 Dec;118(2):201-10. doi: 10.1016/s0166-6851(01)00371-1.
184 Ficolin-2 levels and genetic polymorphisms of FCN2 in malaria.Hum Immunol. 2011 Jan;72(1):74-9. doi: 10.1016/j.humimm.2010.10.003. Epub 2010 Oct 30.
185 Deficiency of two red-cell flavin enzymes in a population in Sardinia: was glutathione reductase deficiency specifically selected for by malaria?.Am J Hum Genet. 1995 Sep;57(3):674-81.
186 Glycophorin C (Gerbich antigen blood group) and band 3 polymorphisms in two malaria holoendemic regions of Papua New Guinea.Am J Hematol. 2004 Jan;75(1):1-5. doi: 10.1002/ajh.10448.
187 Analysis of the genetic variants of glucose-6-phosphate dehydrogenase in inhabitants of the 4th Nile cataract region in Sudan.Blood Cells Mol Dis. 2013 Feb;50(2):115-8. doi: 10.1016/j.bcmd.2012.10.003. Epub 2012 Nov 10.
188 Transient Expression of Plasmodium berghei MSP8 and HAP2 in the Marine Protozoan Parasite Perkinsus marinus.J Parasitol. 2017 Feb;103(1):118-122. doi: 10.1645/16-88. Epub 2016 Oct 10.
189 Primaquine in Plasma and Methemoglobinemia in Patients with Malaria Due to Plasmodium vivax in the Brazilian Amazon Basin.Am J Trop Med Hyg. 2017 May;96(5):1171-1175. doi: 10.4269/ajtmh.15-0368. Epub 2017 Apr 5.
190 Plasmodium falciparum signal peptide peptidase is a promising drug target against blood stage malaria.Biochem Biophys Res Commun. 2009 Mar 13;380(3):454-9. doi: 10.1016/j.bbrc.2009.01.083. Epub 2009 Jan 25.
191 An expanded histatin gene polymorphism and test of a possible disease resistant phenotype.Hum Mutat. 1997;10(1):58-64. doi: 10.1002/(SICI)1098-1004(1997)10:1<58::AID-HUMU8>3.0.CO;2-I.
192 IFNGR1 gene promoter polymorphisms and susceptibility to cerebral malaria.J Infect Dis. 2002 Jun 1;185(11):1684-7. doi: 10.1086/340516. Epub 2002 May 17.
193 Genetic evidence of regulatory gene variants of the STAT6, IL10R and FOXP3 locus as a susceptibility factor in uncomplicated malaria and parasitaemia in Congolese children.Malar J. 2013 Jan 8;12:9. doi: 10.1186/1475-2875-12-9.
194 Restricted polymorphisms of the mannose-binding lectin gene in a population of Papua New Guinea.Mutat Res. 2002 Aug 29;505(1-2):87-91. doi: 10.1016/s0027-5107(02)00142-2.
195 Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL- tag.Malar J. 2019 Aug 13;18(1):273. doi: 10.1186/s12936-019-2905-9.
196 Natural Parasite Exposure Induces Protective Human Anti-Malarial Antibodies.Immunity. 2017 Dec 19;47(6):1197-1209.e10. doi: 10.1016/j.immuni.2017.11.007. Epub 2017 Nov 29.
197 Cracking Ali Baba's code.Elife. 2017 Jun 14;6:e28600. doi: 10.7554/eLife.28600.
198 Functional dissection of the catalytic carboxyl-terminal domain of origin recognition complex subunit 1 (PfORC1) of the human malaria parasite Plasmodium falciparum.Eukaryot Cell. 2009 Sep;8(9):1341-51. doi: 10.1128/EC.00170-09. Epub 2009 Jul 24.
199 Pannexin-1 channels contribute to seizure generation in human epileptic brain tissue and in a mouse model of epilepsy.Sci Transl Med. 2018 May 30;10(443):eaar3796. doi: 10.1126/scitranslmed.aar3796.
200 Expression of Plasmodium falciparum G6PD-6PGL in laboratory parasites and in patient isolates in G6PD-deficient and normal Nigerian children.Br J Haematol. 2003 Aug;122(4):662-8. doi: 10.1046/j.1365-2141.2003.04397.x.
201 Predominant cell-mediated immunity in the oral mucosa: gene gun-based vaccination against infectious diseases.J Dermatol Sci. 2003 May;31(3):203-10. doi: 10.1016/s0923-1811(03)00027-6.
202 Genetic variants of RNASE3 (ECP) and susceptibility to severe malaria in Senegalese population.Malar J. 2018 Feb 5;17(1):61. doi: 10.1186/s12936-018-2205-9.
203 Characterization of domains of the phosphoriboprotein P0 of Plasmodium falciparum.Mol Biochem Parasitol. 2000 Apr 15;107(2):143-54. doi: 10.1016/s0166-6851(99)00226-1.
204 Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis.Lancet Infect Dis. 2012 Jun;12(6):457-68. doi: 10.1016/S1473-3099(12)70055-5. Epub 2012 Mar 23.
205 LED fluorescence microscopy: Novel method for malaria diagnosis compared with routine methods.J Infect Public Health. 2017 Nov-Dec;10(6):824-828. doi: 10.1016/j.jiph.2017.01.001. Epub 2017 Mar 6.
206 Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency.Cell Physiol Biochem. 2009;24(5-6):415-28. doi: 10.1159/000257529. Epub 2009 Nov 4.
207 Haptoglobin genotype, anaemia and malaria in Gambian children.Trop Med Int Health. 2008 Jan;13(1):76-82. doi: 10.1111/j.1365-3156.2007.01976.x.
208 Ranking malaria risk factors to guide malaria control efforts in African highlands.PLoS One. 2009 Nov 25;4(11):e8022. doi: 10.1371/journal.pone.0008022.
209 The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.Vaccine. 2007 Jan 15;25(5):886-94. doi: 10.1016/j.vaccine.2006.09.035. Epub 2006 Sep 20.
210 Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmission.Scand J Immunol. 2008 Mar;67(3):270-8. doi: 10.1111/j.1365-3083.2007.02059.x. Epub 2008 Jan 22.
211 Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection.Mol Microbiol. 2008 Jul;69(1):152-63. doi: 10.1111/j.1365-2958.2008.06271.x. Epub 2008 May 5.
212 A variant in the gene FUT9 is associated with susceptibility to placental malaria infection.Hum Mol Genet. 2009 Aug 15;18(16):3136-44. doi: 10.1093/hmg/ddp240. Epub 2009 May 21.
213 Functional characterization of both MAP kinases of the human malaria parasite Plasmodium falciparum by reverse genetics.Mol Microbiol. 2007 Sep;65(5):1170-80. doi: 10.1111/j.1365-2958.2007.05859.x. Epub 2007 Jul 26.
214 A genetic association study in the Gambia using tagging polymorphisms in the major histocompatibility complex class III region implicates a HLA-B associated transcript 2 polymorphism in severe malaria susceptibility.Hum Genet. 2009 Feb;125(1):105-9. doi: 10.1007/s00439-008-0597-2. Epub 2008 Nov 28.
215 Purification of human malaria parasite hypoxanthine guanine xanthine phosphoribosyltransferase (HGXPRT) using immobilized Reactive Red 120.Protein Expr Purif. 2007 Mar;52(1):153-8. doi: 10.1016/j.pep.2006.09.014. Epub 2006 Oct 5.
216 Intramembrane proteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase.FASEB J. 2006 Aug;20(10):1671-9. doi: 10.1096/fj.06-5762com.
217 Spectrin-based skeleton in red blood cells and malaria.Curr Opin Hematol. 2007 May;14(3):198-202. doi: 10.1097/MOH.0b013e3280d21afd.
218 Environmental influence on the worldwide prevalence of a 776C->G variant in the transcobalamin gene (TCN2).J Med Genet. 2007 Jun;44(6):363-7. doi: 10.1136/jmg.2006.048041. Epub 2007 Jan 12.
219 Gene silencing through RNAi and antisense Vivo-Morpholino increases the efficacy of pyrethroids on larvae of Anopheles stephensi.Malar J. 2019 Aug 28;18(1):294. doi: 10.1186/s12936-019-2925-5.
220 'I could not join because I had to work for pay.': A qualitative evaluation of falciparum malaria pro-active case detection in three rural Cambodian villages.PLoS One. 2018 Apr 12;13(4):e0195809. doi: 10.1371/journal.pone.0195809. eCollection 2018.
221 Adaptation to past malarial endemia and susceptibility to common diseases in modern populations: a study of adenosine deaminase and MN blood group genetic polymorphisms.Am J Phys Anthropol. 2005 Sep;128(1):194-8. doi: 10.1002/ajpa.20019.
222 Whole-Genome Sequencing of African Dogs Provides Insights into Adaptations against Tropical Parasites.Mol Biol Evol. 2018 Feb 1;35(2):287-298. doi: 10.1093/molbev/msx258.
223 Protective role of brain water channel AQP4 in murine cerebral malaria.Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):1035-40. doi: 10.1073/pnas.1220566110. Epub 2012 Dec 31.
224 Homozygosity for the CD1E*02 allele is associated with a resistance to Plasmodium falciparum malaria infection in Gabonese school children.Asian Pac J Trop Med. 2017 Feb;10(2):204-207. doi: 10.1016/j.apjtm.2017.01.017. Epub 2017 Jan 20.
225 Imputation-based meta-analysis of severe malaria in three African populations.PLoS Genet. 2013 May;9(5):e1003509. doi: 10.1371/journal.pgen.1003509. Epub 2013 May 23.
226 Novel genetic polymorphisms associated with severe malaria and under selective pressure in North-eastern Tanzania.PLoS Genet. 2018 Jan 30;14(1):e1007172. doi: 10.1371/journal.pgen.1007172. eCollection 2018 Jan.
227 Cytochrome P450 Mono-Oxygenase and Resistance Phenotype in DDT and Deltamethrin-Resistant Anopheles gambiae (Diptera: Culicidae) and Culex quinquefasciatus in Kosofe, Lagos, Nigeria.J Med Entomol. 2019 Apr 16;56(3):817-821. doi: 10.1093/jme/tjz006.
228 DDX39B (BAT1), TNF and IL6 gene polymorphisms and association with clinical outcomes of patients with Plasmodium vivax malaria.Malar J. 2014 Jul 19;13:278. doi: 10.1186/1475-2875-13-278.
229 Mitochondrial type II NADH dehydrogenase of Plasmodium falciparum (PfNDH2) is dispensable in the asexual blood stages.PLoS One. 2019 Apr 9;14(4):e0214023. doi: 10.1371/journal.pone.0214023. eCollection 2019.
230 Seasonal malaria vector and transmission dynamics in western Burkina Faso.Malar J. 2019 Apr 2;18(1):113. doi: 10.1186/s12936-019-2747-5.
231 ELF4 facilitates innate host defenses against Plasmodium by activating transcription of Pf4 and Ppbp.J Biol Chem. 2019 May 10;294(19):7787-7796. doi: 10.1074/jbc.RA118.006321. Epub 2019 Mar 21.
232 Associations between IgG reactivity to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) antigens and Burkitt lymphoma in Ghana and Uganda case-control studies.EBioMedicine. 2019 Jan;39:358-368. doi: 10.1016/j.ebiom.2018.12.020. Epub 2018 Dec 20.
233 Flt3 ligand expands bona fide innate lymphoid cell precursors in vivo.Sci Rep. 2018 Jan 9;8(1):154. doi: 10.1038/s41598-017-18283-0.
234 An ImmunoPEGliposome for Targeted Antimalarial Combination Therapy at the Nanoscale.Pharmaceutics. 2019 Jul 16;11(7):341. doi: 10.3390/pharmaceutics11070341.
235 Genome-wide association study indicates two novel resistance loci for severe malaria.Nature. 2012 Sep 20;489(7416):443-6. doi: 10.1038/nature11334. Epub 2012 Aug 15.
236 The Plasmodium falciparum Hsp70-x chaperone assists the heat stress response of the malaria parasite.FASEB J. 2019 Dec;33(12):14611-14624. doi: 10.1096/fj.201901741R. Epub 2019 Nov 14.
237 Ten years malaria trend at Arjo-Didessa sugar development site and its vicinity, Southwest Ethiopia: a retrospective study.Malar J. 2019 Apr 24;18(1):145. doi: 10.1186/s12936-019-2777-z.
238 NF90 regulation of immune factor expression in response to malaria antigens.Cell Cycle. 2019 Mar-Apr;18(6-7):708-722. doi: 10.1080/15384101.2019.1580496. Epub 2019 Mar 8.
239 Use of anthropophilic culicid-based xenosurveillance as a proxy for Plasmodium vivax malaria burden and transmission hotspots identification.PLoS Negl Trop Dis. 2018 Nov 12;12(11):e0006909. doi: 10.1371/journal.pntd.0006909. eCollection 2018 Nov.
240 Functional genetic evaluation of DNA house-cleaning enzymes in the malaria parasite: dUTPase and Ap4AH are essential in Plasmodium berghei but ITPase and NDH are dispensable.Expert Opin Ther Targets. 2019 Mar;23(3):251-261. doi: 10.1080/14728222.2019.1575810. Epub 2019 Feb 13.
241 Side chain rotameric changes and backbone dynamics enable specific cladosporin binding in Plasmodium falciparum lysyl-tRNA synthetase.Proteins. 2019 Sep;87(9):730-737. doi: 10.1002/prot.25699. Epub 2019 May 9.
242 Rubber plantations and drug resistant malaria: a cross-sectional survey in Cambodia.Malar J. 2019 Nov 27;18(1):379. doi: 10.1186/s12936-019-3000-y.
243 Sample-to-answer palm-sized nucleic acid testing device towards low-cost malaria mass screening.Biosens Bioelectron. 2018 Sep 15;115:83-90. doi: 10.1016/j.bios.2018.05.019. Epub 2018 May 19.
244 A marker of glutathione S-transferase-mediated resistance to insecticides is associated with higher Plasmodium infection in the African malaria vector Anopheles funestus.Sci Rep. 2019 Apr 8;9(1):5772. doi: 10.1038/s41598-019-42015-1.
245 First genome-wide association study of non-severe malaria in two birth cohorts in Benin.Hum Genet. 2019 Dec;138(11-12):1341-1357. doi: 10.1007/s00439-019-02079-5. Epub 2019 Oct 30.
246 The use of GPS data loggers to describe the impact of spatio-temporal movement patterns on malaria control in a high-transmission area of northern Zambia.Int J Health Geogr. 2019 Aug 19;18(1):19. doi: 10.1186/s12942-019-0183-y.
247 Beyond genome-wide scan: Association of a cis-regulatory NCR3 variant with mild malaria in a population living in the Republic of Congo.PLoS One. 2017 Nov 9;12(11):e0187818. doi: 10.1371/journal.pone.0187818. eCollection 2017.
248 Malaria transmission through the mosquito requires the function of the OMD protein.PLoS One. 2019 Sep 25;14(9):e0222226. doi: 10.1371/journal.pone.0222226. eCollection 2019.
249 Haptoglobin phenotypes and iron status in children living in a malaria endemic area of Kenyan coast.Acta Trop. 2013 May;126(2):127-31. doi: 10.1016/j.actatropica.2013.02.004. Epub 2013 Feb 13.
250 A neurotoxin that specifically targets Anopheles mosquitoes.Nat Commun. 2019 Jun 28;10(1):2869. doi: 10.1038/s41467-019-10732-w.
251 Common PIEZO1 Allele in African Populations Causes RBC Dehydration and Attenuates Plasmodium Infection.Cell. 2018 Apr 5;173(2):443-455.e12. doi: 10.1016/j.cell.2018.02.047. Epub 2018 Mar 22.
252 Genome-wide and fine-resolution association analysis of malaria in West Africa.Nat Genet. 2009 Jun;41(6):657-65. doi: 10.1038/ng.388. Epub 2009 May 24.
253 Controlled human malaria infection with Plasmodium falciparum demonstrates impact of naturally acquired immunity on virulence gene expression.PLoS Pathog. 2019 Jul 11;15(7):e1007906. doi: 10.1371/journal.ppat.1007906. eCollection 2019 Jul.
254 Puf3 participates in ribosomal biogenesis in malaria parasites.J Cell Sci. 2018 Mar 26;131(6):jcs212597. doi: 10.1242/jcs.212597.
255 Whole-genome sequencing reveals high complexity of copy number variation at insecticide resistance loci in malaria mosquitoes.Genome Res. 2019 Aug;29(8):1250-1261. doi: 10.1101/gr.245795.118. Epub 2019 Jul 25.
256 Retrospective analysis of risk factors of slide positivity among febrile patients in the Salween river valley of Shan Special Region II, northern Myanmar.BMC Public Health. 2018 Apr 27;18(1):560. doi: 10.1186/s12889-018-5469-7.
257 Negligible Impact of Mass Screening and Treatment on Mesoendemic Malaria Transmission at West Timor in Eastern Indonesia: A Cluster-Randomized Trial.Clin Infect Dis. 2018 Oct 15;67(9):1364-1372. doi: 10.1093/cid/ciy231.
258 Significant association between TIM1 promoter polymorphisms and protection against cerebral malaria in Thailand.Ann Hum Genet. 2008 May;72(Pt 3):327-36. doi: 10.1111/j.1469-1809.2007.00424.x. Epub 2008 Feb 19.
259 TOLLIP gene variant is associated with Plasmodium vivax malaria in the Brazilian Amazon.Malar J. 2017 Mar 13;16(1):116. doi: 10.1186/s12936-017-1754-7.
260 Unusual dynamics of the divergent malaria parasite PfAct1 actin filament.Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20418-20427. doi: 10.1073/pnas.1906600116. Epub 2019 Sep 23.
261 Roll Back Malaria: an historical footnote.Malar J. 2018 Nov 19;17(1):433. doi: 10.1186/s12936-018-2582-0.
262 Fermentation and downstream process for high yield production of Plasmodium falciparum recombinant HRP II protein and its application in diagnosis.J Ind Microbiol Biotechnol. 2013 Jul;40(7):687-95. doi: 10.1007/s10295-013-1270-x. Epub 2013 Apr 23.
263 Novel inhibitors of Plasmodium falciparum based on 2,5-disubstituted furans.Eur J Med Chem. 2017 Jan 27;126:929-936. doi: 10.1016/j.ejmech.2016.12.024. Epub 2016 Dec 11.
264 The T-Cell Inhibitory Molecule Butyrophilin-Like 2 Is Up-regulated in Mild Plasmodium falciparum Infection and Is Protective During Experimental Cerebral Malaria.J Infect Dis. 2015 Oct 15;212(8):1322-31. doi: 10.1093/infdis/jiv217. Epub 2015 Apr 15.
265 CCL3L1 copy number and susceptibility to malaria.Infect Genet Evol. 2012 Jul;12(5):1147-54. doi: 10.1016/j.meegid.2012.03.021. Epub 2012 Mar 30.
266 The Malaria Parasite Cyclin H Homolog PfCyc1 Is Required for Efficient Cytokinesis in Blood-Stage Plasmodium falciparum.mBio. 2017 Jun 13;8(3):e00605-17. doi: 10.1128/mBio.00605-17.
267 Cryptic genetic diversity within the Anopheles nili group of malaria vectors in the equatorial forest area of Cameroon (Central Africa).PLoS One. 2013;8(3):e58862. doi: 10.1371/journal.pone.0058862. Epub 2013 Mar 14.
268 Distinct effects of HIV protease inhibitors and ERAD inhibitors on zygote to ookinete transition of the malaria parasite.Mol Biochem Parasitol. 2018 Mar;220:10-14. doi: 10.1016/j.molbiopara.2017.12.003. Epub 2018 Jan 3.
269 cGAS-mediated control of blood-stage malaria promotes Plasmodium-specific germinal center responses.JCI Insight. 2018 Jan 25;3(2):e94142. doi: 10.1172/jci.insight.94142. eCollection 2018 Jan 25.
270 Plasmodium falciparum dipeptidyl aminopeptidase 3 activity is important for efficient erythrocyte invasion by the malaria parasite.PLoS Pathog. 2018 May 16;14(5):e1007031. doi: 10.1371/journal.ppat.1007031. eCollection 2018 May.
271 Sequence diversity and positive selection at the Duffy-binding protein genes of Plasmodium knowlesi and P. cynomolgi: Analysis of the complete coding sequences of Thai isolates.Infect Genet Evol. 2016 Oct;44:367-375. doi: 10.1016/j.meegid.2016.07.040. Epub 2016 Jul 30.
272 Minimal requirements for actin filament disassembly revealed by structural analysis of malaria parasite actin-depolymerizing factor 1.Proc Natl Acad Sci U S A. 2011 Jun 14;108(24):9869-74. doi: 10.1073/pnas.1018927108. Epub 2011 May 31.
273 Anemia Offers Stronger Protection Than Sickle Cell Trait Against the Erythrocytic Stage of Falciparum Malaria and This Protection Is Reversed by Iron Supplementation.EBioMedicine. 2016 Dec;14:123-130. doi: 10.1016/j.ebiom.2016.11.011. Epub 2016 Nov 9.
274 Erythroferrone contributes to hepcidin repression in a mouse model of malarial anemia.Haematologica. 2017 Jan;102(1):60-68. doi: 10.3324/haematol.2016.150227. Epub 2016 Sep 22.
275 Malaria parasites possess a telomere repeat-binding protein that shares ancestry with transcription factor IIIA.Nat Microbiol. 2017 Mar 13;2:17033. doi: 10.1038/nmicrobiol.2017.33.
276 Evolutionary context for the association of -globin, serum uric acid, and hypertension in African Americans.BMC Med Genet. 2015 Nov 5;16:103. doi: 10.1186/s12881-015-0249-z.
277 Individual variation in levels of haptoglobin-related protein in children from Gabon.PLoS One. 2012;7(11):e49816. doi: 10.1371/journal.pone.0049816. Epub 2012 Nov 20.
278 Association of cytokine and Toll-like receptor gene polymorphisms with severe malaria in three regions of Cameroon.PLoS One. 2013 Nov 27;8(11):e81071. doi: 10.1371/journal.pone.0081071. eCollection 2013.
279 Killer-cell immunoglobulin-like receptors and falciparum malaria in southwest Nigeria.Hum Immunol. 2014 Aug;75(8):816-21. doi: 10.1016/j.humimm.2014.06.002. Epub 2014 Jun 11.
280 Differential association of KIR gene loci to risk of malaria in ethnic groups of Assam, Northeast India.Infect Genet Evol. 2011 Dec;11(8):1921-8. doi: 10.1016/j.meegid.2011.08.017. Epub 2011 Aug 25.
281 High Incidence of Malaria Along the Sino-Burmese Border Is Associated With Polymorphisms of CR1, IL-1A, IL-4R, IL-4, NOS, and TNF, But Not With G6PD Deficiency.Medicine (Baltimore). 2015 Oct;94(40):e1681. doi: 10.1097/MD.0000000000001681.
282 The transcription factor Maf-S regulates metabolic resistance to insecticides in the malaria vector Anopheles gambiae.BMC Genomics. 2017 Aug 30;18(1):669. doi: 10.1186/s12864-017-4086-7.
283 Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.J Infect Dis. 2017 Jan 1;215(1):88-94. doi: 10.1093/infdis/jiw495. Epub 2016 Oct 25.
284 Microcrystalline Tyrosine (MCT()): A Depot Adjuvant in Licensed Allergy Immunotherapy Offers New Opportunities in Malaria.Vaccines (Basel). 2017 Sep 27;5(4):32. doi: 10.3390/vaccines5040032.
285 Worldwide population genetic analysis and natural selection in the Plasmodium vivax Generative Cell Specific 1 (PvGCS1) as a transmission-blocking vaccine candidate.Infect Genet Evol. 2016 Sep;43:50-7. doi: 10.1016/j.meegid.2016.05.015. Epub 2016 May 13.
286 Profiling MHC II immunopeptidome of blood-stage malaria reveals that cDC1 control the functionality of parasite-specific CD4 T cells.EMBO Mol Med. 2017 Nov;9(11):1605-1621. doi: 10.15252/emmm.201708123.
287 Malaria-induced NLRP12/NLRP3-dependent caspase-1 activation mediates inflammation and hypersensitivity to bacterial superinfection.PLoS Pathog. 2014 Jan;10(1):e1003885. doi: 10.1371/journal.ppat.1003885. Epub 2014 Jan 16.
288 Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase.ACS Infect Dis. 2017 Jan 13;3(1):34-44. doi: 10.1021/acsinfecdis.6b00078. Epub 2016 Nov 16.
289 Virtual Screening, Molecular Dynamics and ADME-Tox Tools for Finding Potential Inhibitors of Phosphoglycerate Mutase 1 from Plasmodium falciparum.Curr Top Med Chem. 2018;18(18):1610-1617. doi: 10.2174/1568026618666181029144653.
290 Protein O-fucosylation in Plasmodium falciparum ensures efficient infection of mosquito and vertebrate hosts.Nat Commun. 2017 Sep 15;8(1):561. doi: 10.1038/s41467-017-00571-y.
291 Low genetic diversity and functional constraint in loci encoding Plasmodium vivax P12 and P38 proteins in the Colombian population.Malar J. 2014 Feb 18;13:58. doi: 10.1186/1475-2875-13-58.
292 From malaria to cancer: Computational drug repositioning of amodiaquine using PLIP interaction patterns.Sci Rep. 2017 Sep 12;7(1):11401. doi: 10.1038/s41598-017-11924-4.
293 Rab GTPase regulation of bacteria and protozoa phagocytosis occurs through the modulation of phagocytic receptor surface expression.Sci Rep. 2018 Aug 29;8(1):12998. doi: 10.1038/s41598-018-31171-5.
294 Characterization of Plasmodium ovale curtisi and P. ovale wallikeri in Western Kenya utilizing a novel species-specific real-time PCR assay.PLoS Negl Trop Dis. 2015 Jan 15;9(1):e0003469. doi: 10.1371/journal.pntd.0003469. eCollection 2015 Jan.
295 Inhibition of the SR protein-phosphorylating CLK kinases of Plasmodium falciparum impairs blood stage replication and malaria transmission.PLoS One. 2014 Sep 4;9(9):e105732. doi: 10.1371/journal.pone.0105732. eCollection 2014.
296 Evaluating the Causal Link Between Malaria Infection and Endemic Burkitt Lymphoma in Northern Uganda: A Mendelian Randomization Study.EBioMedicine. 2017 Nov;25:58-65. doi: 10.1016/j.ebiom.2017.09.037. Epub 2017 Oct 3.
297 Effectiveness of insecticide-treated bednets in malaria prevention in Haiti: a case-control study.Lancet Glob Health. 2017 Jan;5(1):e96-e103. doi: 10.1016/S2214-109X(16)30238-8. Epub 2016 Nov 26.
298 Rapid diagnostic tests as a source of DNA for Plasmodium species-specific real-time PCR.Malar J. 2011 Mar 24;10:67. doi: 10.1186/1475-2875-10-67.
299 Multifunctional Involvement of a C2H2 Zinc Finger Protein (PbZfp) in Malaria Transmission, Histone Modification, and Susceptibility to DNA Damage Response.mBio. 2017 Aug 29;8(4):e01298-17. doi: 10.1128/mBio.01298-17.
300 Further observations on associations between the ADA gene and past malaria morbidity in Sardinia.Am J Hum Biol. 2014 Sep-Oct;26(5):716-8. doi: 10.1002/ajhb.22580. Epub 2014 Jun 26.
301 Triggering receptor expressed on myeloid cells 1 (TREM-1) and cytokine gene variants in complicated and uncomplicated malaria.Trop Med Int Health. 2016 Dec;21(12):1592-1601. doi: 10.1111/tmi.12787. Epub 2016 Oct 24.
302 Genetic polymorphisms associated with anti-malarial antibody levels in a low and unstable malaria transmission area in southern Sri Lanka.Malar J. 2012 Aug 20;11:281. doi: 10.1186/1475-2875-11-281.